Study of serum syndecan-1 levels in a group of Egyptian juvenile systemic lupus erythematosus patients

Immunol Lett. 2017 Jan:181:16-19. doi: 10.1016/j.imlet.2016.11.005. Epub 2016 Nov 9.

Abstract

The aim of the study was to assess the serum levels of Syndecan-1 in a group of Egyptian juvenile systemic lupus erythematosus (JSLE) patients and to study any possible associations with disease activity, renal activity and organ damage. Serum level of Syndecan-1 was assessed in 60 Egyptian JSLE patients and 30 apparently healthy age and gender matched children using ELISA. SLE Disease Activity Index-2000 (SLEDAI-2K), renal SLEDAI-2K, renal activity score and the Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index were assessed for all patients. Serum SDC-1 levels were higher in patients with JSLE than in healthy controls (p<0.001) and were positively correlated with SLEDAI-2K (p<0.001), with renal SLEDAI score (p=0.008) and renal activity score (p=0.04). So, Syndecan-1 might be used as a marker for disease activity and renal activity in JSLE patients.

Keywords: Juvenile systemic lupus erythematosus; Lupus nephritis; Syndecan-1.

MeSH terms

  • Adolescent
  • Age Factors
  • Biomarkers
  • Child
  • Child, Preschool
  • Disease Progression
  • Egypt
  • Female
  • Humans
  • Lupus Erythematosus, Systemic / blood*
  • Lupus Erythematosus, Systemic / diagnosis*
  • Male
  • Prognosis
  • Severity of Illness Index
  • Symptom Assessment
  • Syndecan-1 / blood*

Substances

  • Biomarkers
  • Syndecan-1